Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort

Autor: Mouritzen, M., Bjoernhart, B., Poehl, M., Ladekarl, M., Vesteghem, C., Boegsted, M., Nielsen, A.W. Moelby, Meldgaard, P., Hansen, K.H., Larsen, J.W.W., Kristiansen, C., Wedervang, K., Bareid-Oestby, A-C., Frank, M.S., Persson, G., Kristensen, E.B., Homann, P.H., Carus, A.

Publikováno v: Mouritzen, M, Bjoernhart, B, Poehl, M, Ladekarl, M, Vesteghem, C, Boegsted, M, Nielsen, A W M, Meldgaard, P, Hansen, K H, Larsen, J W W, Kristiansen, C, Wedervang, K, Bareid-Oestby, A-C, Frank, M S, Persson, G, Kristensen, E B, Homann, P H & Carus, A 2020, ' Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort ', Annals of Oncology, vol. 31, no. Suppl. 4, 1334P, pp. S858 . https://doi.org/10.1016/j.annonc.2020.08.1648
Mouritzen, M, Bjørnhart, B, Pøhl, M, Ladekarl, M, Vesteghem, C, Bøgsted, M, Moelby Nielsen, A W, Meldgaard, P, Holmskov Hansen, K, Larsen, J W W, Kristiansen, C, Wedervang, K, Bareid-Oestby, A C, Frank, M S, Persson, G, Kirstensen, E B, Hormann, P H & Carus, A 2020, ' Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort ', Annals of Oncology, vol. 31, no. Suppl. 4, 1334P . https://doi.org/10.1016/j.annonc.2020.08.1648

BackgroundImmune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced non-small cell lung cancer (NSCLC). In the pivotal Keynote-024 study with highly selected patients, pembrolizumab improved survival compared with pla

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::10fd688e5f4f8ff43273a84d0cb636f6
https://vbn.aau.dk/da/publications/4c9dbe1d-68f1-4c67-bb9c-af0e8f9ea219